Contact
searchSearch
HMP Global
Login

Hepatocellular Carcinoma Excellence Forum

Hepatocellular Carcinoma
Excellence Forum
Leaders in the field sharing authoritative insights and institutional best practices.

Olatunji Alese, MD, Winship Cancer Center
Videos
Dual Immune Checkpoint Blockade for Advanced Hepatocellular Carcinoma
09/17/2025
O. Alese
Olatunji Alese, MD, discusses the use of dual immune checkpoint blockade, for frontline therapy and sequencing, for patients with advanced hepatocellular carcinoma.
Olatunji Alese, MD, discusses the use of dual immune checkpoint blockade, for frontline therapy and sequencing, for patients with advanced hepatocellular carcinoma.
Olatunji Alese, MD, discusses...
09/17/2025
Oncology
Ruth He, MD
Videos
Frontline Nivolumab Plus Ipilimumab for Patients With Unresectable Hepatocellular Carcinoma
04/15/2025
Aiwu Ruth He, MD, PhD
Ruth He, MD, PhD, discusses results from the CheckMate 9DW trial which evaluating nivolumab plus ipilimumab in the first-line setting for unresectable hepatocellular carcinoma.
Ruth He, MD, PhD, discusses results from the CheckMate 9DW trial which evaluating nivolumab plus ipilimumab in the first-line setting for unresectable hepatocellular carcinoma.
Ruth He, MD, PhD, discusses...
04/15/2025
Oncology
Ian Tobal, DO, Ochsner Medical Center
Videos
Real World Child-Pugh Scores of Patients With HCC Receiving Immunotherapy
03/27/2025
Ian Tobal, DO, discusses an analysis of real-world Child-Pugh score and outcomes among patients undergoing treatment for hepatocellular carcinoma.
Ian Tobal, DO, discusses an analysis of real-world Child-Pugh score and outcomes among patients undergoing treatment for hepatocellular carcinoma.
Ian Tobal, DO, discusses an...
03/27/2025
Oncology
Laura Dawson, MD, Princess Margaret Cancer Care
Videos
Addition of SBRT to Sorafenib for Patients With Locally Advanced Hepatocellular Carcinoma
03/11/2025
Laura Dawson, MD
Laura Dawson, MD, discusses the results of a phase 3 study comparing stereotactic body radiotherapy followed by sorafenib to sorafenib alone for patients with locally advanced hepatocellular carcinoma.
Laura Dawson, MD, discusses the results of a phase 3 study comparing stereotactic body radiotherapy followed by sorafenib to sorafenib alone for patients with locally advanced hepatocellular carcinoma.
Laura Dawson, MD, discusses the...
03/11/2025
Oncology
Richard Finn, MD
Videos
Tiragolumab Plus Atezolizumab and Bevacizumab for Patients With Hepatocellular Carcinoma
03/05/2025
Richard Finn, MD, discusses results from the phase 1b/2 MORPHEUS-Liver trial which demonstrated that the addition of tiragolumab to atezolizumab plus bevacizumab showed promise for patients with previously untreated, locally advanced or...
Richard Finn, MD, discusses results from the phase 1b/2 MORPHEUS-Liver trial which demonstrated that the addition of tiragolumab to atezolizumab plus bevacizumab showed promise for patients with previously untreated, locally advanced or...
Richard Finn, MD, discusses...
03/05/2025
Oncology
Boris Pasche, MD, PhD
Novel Electromagnetic Field Device for Advanced Hepatocellular Carcinoma
02/27/2025
Boris Pasche, MD, PhD
According to study results, a novel device, which emits electromagnetic fields that are amplitude-modulated at hepatocellular carcinoma frequencies, was found to have a reasonable assurance of safety and probable benefit.
According to study results, a novel device, which emits electromagnetic fields that are amplitude-modulated at hepatocellular carcinoma frequencies, was found to have a reasonable assurance of safety and probable benefit.
According to study results, a...
02/27/2025
Oncology
Christopher Manz, MD, MSPH, Dana-Farber Cancer Institute
Videos
Treatment Patterns for Hepatocellular Carcinoma
12/18/2024
Christopher Manz, MD, MSHP, discusses results from a retrospective study evaluating the evolving treatment patterns for hepatocellular carcinoma.
Christopher Manz, MD, MSHP, discusses results from a retrospective study evaluating the evolving treatment patterns for hepatocellular carcinoma.
Christopher Manz, MD, MSHP,...
12/18/2024
Oncology
Riccardo Lencioni, MD, University of Pisa School of Medicine
Videos
Addition of Durvalumab, Bevacizumab to TACE for Hepatocellular Carcinoma Improves PFS
01/23/2024
Riccardo Lencioni, MD
Ricardo Lencioni, MD, shares results from the phase 3 EMERALD-1 study which found the addition of durvalumab and bevacizumab to TACE improved progression-free survival among patients with hepatocellular carcinoma, compared with TACE alone.
Ricardo Lencioni, MD, shares results from the phase 3 EMERALD-1 study which found the addition of durvalumab and bevacizumab to TACE improved progression-free survival among patients with hepatocellular carcinoma, compared with TACE alone.
Ricardo Lencioni, MD, shares...
01/23/2024
Oncology
Quiz
STRIDE vs Sorafenib for Unresectable Hepatocellular Carcinoma
10/05/2023
Which treatment was associated with a better chance of survival at 4 years for patients with unresectable hepatocellular carcinoma?
Which treatment was associated with a better chance of survival at 4 years for patients with unresectable hepatocellular carcinoma?
Which treatment was associated...
10/05/2023
Oncology
Bruno Sangro, MD, PhD, Clínica Universidad de Navarra
Videos
Long-Term OS Benefit of STRIDE Regimen Among Patients With Unresectable Hepatocellular Carcinoma
08/21/2023
Bruno Sangro, MD, PhD
At the 2023 World Congress on Gastrointestinal Cancers, Bruno Sangro, MD, PhD, discusses 4-year overall survival results from the phase 3 HIMALYA study.
At the 2023 World Congress on Gastrointestinal Cancers, Bruno Sangro, MD, PhD, discusses 4-year overall survival results from the phase 3 HIMALYA study.
At the 2023 World Congress on...
08/21/2023
Oncology

Recent News

News
Genotype-Guided Therapy Demonstrates High Response and Survival Rates for Patients With R/R DLBCL
09/26/2025
Emily Estrada
The implementation of R-ICE combined with genotype-guided therapy for the treatment of relapsed/refractory diffuse large B-cell lymphoma demonstrated clinical efficacy and safety in a phase 2 trial.
The implementation of R-ICE combined with genotype-guided therapy for the treatment of relapsed/refractory diffuse large B-cell lymphoma demonstrated clinical efficacy and safety in a phase 2 trial.
The implementation of R-ICE...
09/26/2025
Oncology
News
PD-1/PD-L1 Inhibitor Monotherapy Demonstrates Accceptable Safety, Limited Efficacy for R/R DLBCL
09/26/2025
Emily Estrada
Treatment of R/R diffuse large B-cell lymphoma with PD-1/PD-L1 inhibitors alone showed consistent safety but limited efficacy, while combination treatment with CAR T-cell therapy demonstrated potential improved outcomes.
Treatment of R/R diffuse large B-cell lymphoma with PD-1/PD-L1 inhibitors alone showed consistent safety but limited efficacy, while combination treatment with CAR T-cell therapy demonstrated potential improved outcomes.
Treatment of R/R diffuse large...
09/26/2025
Oncology
News
Polatuzumab-Based Regimens Demonstrate Promising Efficacy for R/R DLBCL Compared to Traditional Salvage Therapies
09/26/2025
Emily Estrada
Compared with traditional salvage therapies, polatuzumab vedotin and zanubrutinib combined with rituximab or obinutuzumab demonstrated encouraging clinical efficacy for patients with relapsed/refractory diffuse large B-cell lymphoma.
Compared with traditional salvage therapies, polatuzumab vedotin and zanubrutinib combined with rituximab or obinutuzumab demonstrated encouraging clinical efficacy for patients with relapsed/refractory diffuse large B-cell lymphoma.
Compared with traditional...
09/26/2025
Oncology
FDA Approval
FDA Approves Imlunestrant for Patients With ER-Positive, HER2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer
09/25/2025
Stephanie Holland
The FDA has approved imlunestrant for patients with ER-positive, HER2-negative advanced or metastatic breast cancer harboring ESR1 mutations.
The FDA has approved imlunestrant for patients with ER-positive, HER2-negative advanced or metastatic breast cancer harboring ESR1 mutations.
The FDA has approved...
09/25/2025
Oncology
News
Pexidartinib Shows Durable Response Among Patients with Tenosynovial Giant Cell Tumors
09/25/2025
Allison Casey
Pexidartinib showed sustained clinical benefit among patients with tenosynovial giant cell tumor associated with severe morbidity or functional limitations and not amenable to surgery.
Pexidartinib showed sustained clinical benefit among patients with tenosynovial giant cell tumor associated with severe morbidity or functional limitations and not amenable to surgery.
Pexidartinib showed sustained...
09/25/2025
Oncology
News
Clarithromycin-Based Quadruplet Therapy Demonstrates Promising Clinical Responses for Treatment of Relapsed/Refractory Multiple Myeloma
09/24/2025
Emily Estrada
For patients with relapsed/refractory multiple myeloma, the combination of clarithromycin, ixazomib, pomalidomide, and dexamethasone demonstrated promising clinical efficacy and a manageable safety profile.
For patients with relapsed/refractory multiple myeloma, the combination of clarithromycin, ixazomib, pomalidomide, and dexamethasone demonstrated promising clinical efficacy and a manageable safety profile.
For patients with...
09/24/2025
Oncology
News
First-Line mFOLFIRINOX, S-IROX Fail to Improve Survival Among Patients With Recurrent or Metastatic Pancreatic Cancer
09/23/2025
Stephanie Holland
Results from the phase 2/3 GENERATE study demonstrated that neither mFOLFIRINOX nor S-IROX improved survival results compared to nab-paclitaxel plus gemcitabine among patients with recurrent or metastatic pancreatic cancer in the first-line...
Results from the phase 2/3 GENERATE study demonstrated that neither mFOLFIRINOX nor S-IROX improved survival results compared to nab-paclitaxel plus gemcitabine among patients with recurrent or metastatic pancreatic cancer in the first-line...
Results from the phase 2/3...
09/23/2025
Oncology
News
Novel Anti-CSF1 Receptor Antibody for Patients With Tenosynovial Giant Cell Tumor
09/23/2025
Allison Casey
According to a phase 2a trial, the novel anti-CSF1 receptor monoclonal antibody, AMB-05X, was found to have favorable pharmacokinetics, pharmacodynamics, efficacy, and safety among patients with tenosynovial giant cell tumors.
According to a phase 2a trial, the novel anti-CSF1 receptor monoclonal antibody, AMB-05X, was found to have favorable pharmacokinetics, pharmacodynamics, efficacy, and safety among patients with tenosynovial giant cell tumors.
According to a phase 2a trial,...
09/23/2025
Oncology
News
Adverse Events With Pexidartinib for Patients With Tenosynovial Giant Cell Tumor
09/23/2025
Allison Casey
According to an analysis of the FDA Adverse Events Reporting System (FAERS) database, the overall safety profile of pexidartinib was generally consistent with the clinical trial findings.
According to an analysis of the FDA Adverse Events Reporting System (FAERS) database, the overall safety profile of pexidartinib was generally consistent with the clinical trial findings.
According to an analysis of the...
09/23/2025
Oncology
News
Trifluridine/Tipiracil Plus Bevacizumab Escalation Demonstrates Promise Among Patients With Advanced or Unresectable Metastatic Colorectal Cancer
09/22/2025
Stephanie Holland
According to results from the phase 2 E-BiTS study, intrapatient escalation of biweekly trifluridine/tipiracil plus bevacizumab demonstrated promising efficacy and safety among patients with advanced or unresectable metastatic colorectal...
According to results from the phase 2 E-BiTS study, intrapatient escalation of biweekly trifluridine/tipiracil plus bevacizumab demonstrated promising efficacy and safety among patients with advanced or unresectable metastatic colorectal...
According to results from the...
09/22/2025
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use